The first FDA-approved systemic therapy may be beneficial to patients with low-grade astrocytoma or oligodendroglioma with IDH1 or 2 mutations. The recent Food and Drug Administration (FDA) approval ...
Eflornithine plus Gleostine improved OS and PFS in recurrent grade 3 IDH-mutated astrocytoma compared to Gleostine alone. The STELLAR study reclassified patients using updated WHO 2021 criteria, ...
The role of the ubiquitin ligase UBE4B in neural tumors in adults and children. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include a full text ...
This can be used to predict patient prognosis and drive the development of novel therapies." Until a cure is found for the most aggressive astrocytomas, the priority for oncologists is to detect their ...
Pilocytic astrocytoma is a generally benign glial neoplasm classified as WHO grade I, most frequently encountered in children and young adults. These tumours exhibit a biphasic histological pattern, ...
The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted ...
A research team has discovered a previously overlooked subtype of brain tumor termed IME IDH-mutant astrocytoma. Contrary to typical medical expectations, this subtype exhibits strong immune activity, ...
Irene Rodríguez-Hernández; Marta Vázquez-Cedeira; Angel Santos-Briz; Juan L García; Isabel F Fernández; Juan A Gómez-Moreta; Javier Martin-Vallejo; Rogelio González-Sarmiento; Pedro A Lazo In summary, ...
Huntsman Cancer Institute at the University of Utah (the U) participated in a clinical trial that found that a new combination treatment plan helped people with recurring grade 3 astrocytoma, an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results